InvivoGen Reviews
Read the Review
RIG-I & cancer immunotherapy
The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer immunotherapy, although complete remission remains limited to a small panel of cancers and patients. ICIs act by relieving checkpoint restraints on antitumor T cell responses. They work best against immunogenic, T-cell inflamed or « hot » tumors. In contrast, ICIs are poorly efficient in «cold» tumor microenvironments (TMEs) that are largely devoid of T cells and infiltrated by immunosuppressive cells.